NVO
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E 11.70, PEG 4.53, Graham Number $23.58
- Low P/E ratio
- Price is ~78% above Graham Number
- High PEG ratio
Ref Revenue Growth -7.60%, Earnings Growth -4.70%
- Analyst target price of $46.67
- Negative YoY revenue and earnings growth
- Bearish technical trend
Ref 25-quarter earnings track record
- Consistent earnings beats
- High historical margins
- Recent 1-year price collapse
Ref Piotroski F-Score, Current Ratio 0.80
- Manageable Debt/Equity (0.67)
- Piotroski F-Score 4/9 (Stable/Mediocre)
- Current Ratio < 1.0
Ref Yield 4.27%, Payout 50.42%
- Strong yield (4.27%)
- Healthy payout ratio (50.42%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NVO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NVO
Novo Nordisk A/S
Primary
|
+24.8% | -45.4% | -33.4% | -12.5% | +14.9% | +9.6% |
|
TMO
Thermo Fisher Scientific Inc.
Peer
|
+6.7% | -9.7% | +18.7% | -9.2% | +7.5% | -3.3% |
|
AMGN
Amgen Inc.
Peer
|
+65.0% | +55.4% | +20.8% | +17.5% | -3.1% | -2.3% |
|
ABT
Abbott Laboratories
Peer
|
-10.8% | +2.5% | -18.4% | -21.1% | -7.6% | -1.9% |
|
ISRG
Intuitive Surgical, Inc.
Peer
|
+56.7% | +55.1% | -0.6% | +1.6% | -2.6% | +1.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NVO
Novo Nordisk A/S
|
NEUTRAL | $187.21B | 11.7 | 60.7% | 33.1% | $42.22 | |
|
TMO
Thermo Fisher Scientific Inc.
|
NEUTRAL | $191.01B | 28.99 | 13.0% | 15.0% | $513.98 | Compare |
|
AMGN
Amgen Inc.
|
NEUTRAL | $182.22B | 23.75 | 106.1% | 21.0% | $338.02 | Compare |
|
ABT
Abbott Laboratories
|
NEUTRAL | $176.48B | 27.3 | 13.0% | 14.7% | $101.56 | Compare |
|
ISRG
Intuitive Surgical, Inc.
|
NEUTRAL | $165.37B | 59.16 | 16.7% | 28.4% | $465.6 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Novo Nordisk (NVO) filed its 20-F annual report on February 4, 2026, providing a comprehensive overview of its yearly financial performance and operational results. The filing details the company's key financial highlights and outlines the strategic, regulatory, and market risks facing its global business.
Novo Nordisk's 20-F filing dated February 5, 2025, details the company's annual financial performance, driven largely by strong demand for its diabetes and obesity care portfolio. Key investor risks include manufacturing capacity constraints to meet global demand and intensifying competition within the GLP-1 therapeutic market.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning NVO from our newsroom.